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Abstract
Background: The patient self-management (PSM) is an effective approach for controlling the international
normalized ratio, INR, within the therapeutic range. Nevertheless, most of the literature derives from randomized
clinical trials, and no from routine clinical practice. The main objective of the present study was to evaluate long-
term effectiveness and safety of PSM of oral anticoagulants (OACs) in real-world settings.
Methods: This prospective cohort study involved 808 patients who were trained for PSM between July 2009 and
March 2012, and followed-up for a maximum observational period of 5 years. The follow-up consisted of a visit to
the physician every 6 months. All patients used the same type of portable coagulometer, able to store digitally up
to 100 INR measurements. Effectiveness outcomes included the percentage of patients within the therapeutic
range, the time within therapeutic range (TTR), and the evolution of the TTR over 365 days of follow-up. Long-term safety
profile of PSM included the incidence of all-cause deaths and complications (thromboembolic or hemorrhagic) reported
between July 2009 and June 2014, and the time to event.
Results: The median follow-up was 3.3 years. The percentage of patients within therapeutic INR target range
was 67.5%. The median TTR was 71.5%. The TTR increased over the follow-up period, either overall and
regarding target INR. All-cause mortality was 2.4 per 100 patient-years (59 cases). The thromboembolic event
rate was 0.9 per 100 patient-years (24 cases). The rate of major hemorrhages was 0.45 per 100 patient-years.
Patients who drop out the PSM to perform the conventional management had greater rates of complications:
2.4, 1.8, and 3.4 per 100 patient-years for thromboembolic complications, major hemorrhagic events, and
mortality, respectively.
Conclusions: The PSM of OACs is effective for maintaining patients within the INR therapeutic range for a long period
of time in routine clinical practice. Results of the present study suggest that its effectiveness is at least comparable to the
conventional management. Moreover, it seems safe in real-world settings, by preventing all-cause mortality, and
thromboembolic and major hemorrhagic complications.
Trial registration: This study was not a trial, thus registration was not required.
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Background
Oral anticoagulants (OACs) are a group of medicines
indicated for preventing thromboembolic events in sus-
ceptible patients [1]. One of the limitations associated
with conventional OACs, such as acenocoumarol (the
most prescribed in Spain), is their pharmacokinetic
variability [2]. Patients, frequently aged over 65 years,
are required to periodically visit healthcare centers for
routine monitoring (checking out if the international
normalized ratio, INR, is within the therapeutic range)
and dose adjustments [3, 4]. The INR therapeutic range
includes values associated with the lowest risk for
experiencing thromboembolic or hemorrhagic events
[5]. Patient self-management (PSM) of OACs, i.e. self-
testing in combination with self-adjustment of doses,
has emerged as an alternative to the conventional
management, especially after the development of coa-
gulometers [6, 7]. Nowadays, portable coagulometers
are effective tools for monitoring INR in an easy and
reliable way [8]. By performing PSM, the patient avoids
periodic visits to the healthcare center. In fact, it has
been associated with an improvement in the quality of
life [9]. International guidelines recommend performing
PSM for long-term conditions, established the target
INR, and having been trained by a healthcare provider
[10, 11]. Some studies have reported a higher time
within the INR therapeutic range in patients perform-
ing PSM, compared with the conventional management
[12, 13]. Furthermore, PSM of OACs have also been
associated with a significant reduction in the number of
treatment complications [14]. There exists enough clin-
ical evidence to confirm that PSM is an effective
approach for controlling INR within the therapeutic
range in patients receiving OACs. Nevertheless, most
of the literature derives from randomized clinical trials
or short-term prospective studies [13, 14]. Therefore,
the main objective of the present study was to evaluate
long-term effectiveness and safety of PSM of OACs in
real-world settings.
Methods
Study design and data source
Between July 2009 and March 2012, the regional
Government of Aragon (Spain) conducted a project for
improving the accessibility of patients to the manage-
ment of OAC. Physician of primary and specialized
centers from the region, could offer, to those patients
that they considered appropriate, perform PSM of
OAC. This prospective cohort study involved the pa-
tients who agreed to PSM and who received training
between July 2009 and March 2012. Physicians could
recruit to PSM (inclusion criteria): adults or legal mi-
nors (with a responsible caregiver); with no physical or
mental impairment (or with a responsible caregiver);
requiring long-term OAC treatment (> 3 months), and
willing to provide data from the coagulometer. The
study consisted of the following periods: recruitment,
training of healthcare professionals, training of patients
(initiated in July 2009), and follow-up of patients (from
the end of training to June 31st 2014). A training
course was offered to all healthcare providers who were
interested in learning about PSM, and consisted of 3
sessions (1 theoretical and 2 practical). Patients also re-
ceived a course, consisting of a theorical and a practical
session. In the practical session, patients learned to use
the coagulometer, collect the blood sample, and adjust
the dose. All patients used the same type of portable
coagulometer (CoaguChek® XS, Roche Diagnostics),
able to store digitally up to 100 INR measurements.
The follow-up consisted of a visit to the physician every
6 months aimed at: downloading INR measurements
from the coagulometer (by using Tao Net, Roche Diag-
nostic); reporting treatment-related complications; and
verifying the dosing. All prospective data were subse-
quently collected by the main investigators for analysis.
Demographic and clinical information from patients was
provided from medical records. All patients signed the
written informed consent to participate in the study. Pro-
cedures were in concordance with the Declaration of
Helsinki, and the Ethical Committee of Aragon.
Study variables
The effectiveness of PSM of OACs was determined by
using INR measurements that were stored in the coagul-
ometer. Only patients who downloaded the INR mea-
surements at least one time from their coagulometers
were included in the effectiveness analysis. The PSM
was considered effective if INR was within therapeutic
target range. Effectiveness outcomes included the per-
centage of patients within the therapeutic range, the
time within therapeutic range (TTR), and the evolution
of the TTR over 365 days of follow-up. Baseline, day 0,
or study initiation was the date in which the patient got
the coagulometer and started to PSM. Long-term safety
profile of PSM included the incidence of all-cause deaths
and complications (thromboembolic or hemorrhagic) re-
ported between July 2009 and June 2014, and the time
to event (TTE). The TTE was calculated as the elapsed
time between the initiation of the patient to PSM and
the development of the event. Hemorrhagic complica-
tions were classified as major or minor, in accordance
with the criteria of the International Society of Throm-
bosis and Haemostasis [15].
Statistical analyses
Continuous variables were expressed as the mean, me-
dian, standard deviation (SD), or interquartile range
(IQR, i.e. first and third quartile of the distribution of
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values), whereas categorical ones as absolute and relative
frequencies. The Rosendaal linear interpolation method
was used to calculate the TTR in each patient [16]. The
correlation between the percentage of patients within
therapeutic INR target range and TTR was analyzed by
using Spearman’s correlation test. Differences in TTR
regarding demographic and clinical characteristics of
patients were performed with the T, Mann-Whitney o
Kruskal-Wallis tests, when appropriate. The evolution
of TTR (after 30, 90, 180, and 365 days since study
initiation) was analyzed by using the paired-T test.
Comparisons of TTR at different time points were car-
ried out by using the one-way ANOVA and Tukey’s
HSD post hoc tests. The impact of demographic and
clinical characteristics of patients on safety variables
was evaluated by using the independent samples T test.
Survival estimations were calculated by using the
Kaplan-Meier methodology and Cox regression ana-
lyses (Hazard ratio, HR, 95% confidence interval, 95%
CI). Covariates evaluated in these analyses were: follow-
up period (≤2 years versus > 2 years), TTR (≤65% versus
> 65%), and age (≤60 years versus > 60). Safety variables
depending on the time of follow-up (first 2 years versus
after 2 years) were evaluated by using the Fisher Exact
test. Logistic regression models were also created to
identify variables associated with experiencing an event
(mortality or any complication). Variables initially
included in modes were: age, gender, indication for
anticoagulation, target INR, and efficacy outcomes
(TTR, TTE). All demographic and clinical variables
from patients were included in the model (Odd ratio,
OR). The incidence of events (death, and thrombo-
embolic or hemorrhagic complications) were finally
compared between patients who performed PSM
during the follow-up period and those who did not so.
Statistical significance was established when P ≤ 0.05.
All statistical procedures were performed with SPSS
15.0 version.
Results
Patients
A total of 808 patients were included in the study (Fig. 1).
Demographic and clinical characteristics of patients and
treatments are shown in Table 1. Patients were predom-
inantly male (61.8%), aged between 60 and 75 years
(38.5%), receiving acenocoumarol (97.9%), with a target
INR between 2.0 and 3.0 (75.5%), for preventing mainly
atrial fibrillation/atrial flutter (42.6%). The median fol-
low-up period was 3.3 years (IQR 2.4–4.0). A total of
107 patients (14.0%) required a responsible caregiver to
perform adequately PSM. At the end of the study, 631
patients (78.1%) continued with PSM. Death (7.3%) and
end of treatment (5.2%) were the main reasons of study
withdrawal.
Effectiveness of PSM
Of 808 patients, 476 (58.9%) downloaded the INR mea-
surements at least one time from their coagulometers;
therefore, they were included in the effectiveness ana-
lysis. The percentage of patients within therapeutic INR
target range was 67.5% (from 49,982 INR measurements,
in a total of 385,573 days of follow-up). The median
TTR was 71.5%. The TTR was below 60% in 81 patients
(17.0%), between 60 and 70% in 130 (27.3%), and above
70% in 265 patients (55.7%). A significant positive linear
correlation was found between the percentage of pa-
tients within therapeutic INR target range and the TTR
(Spearman’s rho correlation coefficient: 0.92; P < 0.001).
Fig. 1 Flowchart of patients and phases of the study. PSM, patient self-management; INR, international normalized ratio
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Time in therapeutic range regarding demographic and
clinical characteristics of patients is shown in Table 2.
Significant differences in TTR was found regarding: gen-
der (higher in women, 72.6%, versus men, 70.6%; P <
0.026), target INR (higher in INR 2.0–3.0, 73.9%, versus
INR 2.5–3.5, 65.6%; P < 0.001), and indication for antic-
oagulation (higher in atrial fibrillation/flutter, 73.5%, and
venous and arterial thrombosis, 73.1%, versus mechan-
ical heart valve, 67.2%; P < 0.001). No differences in TTR
were found regarding age group, and origin of the pa-
tient (data not shown). The TTR increased over the fol-
low-up period, both overall and regarding target INR
(Fig. 2). However, significance differences (P < 0.05) were
only found between 30 days (after study start) and the
following time points (90, 180, and 365 days). Patients
with target INR between 2.0 and 3.0 showed significant
higher TTR after 90 (71.1%), 180 (72.3%), and 365 days
(72.9%) than those between 2.5 and 3.5 (64.2, 64.6, and
64.9%, respectively, P < 0.01).
Safety of PSM
Of 808 patients, information about safety was available
in 800 (99.0%); thus, they were included in the safety
analysis. Fifty-nine patients died during the study period.
All-cause mortality rate was 2.4 per 100 patient-years.
The mean age of patients who died was significantly
higher (71.8 years, SD 11.8) than those who did not so
(61.0 years, SD 13.6). The incidence of mortality was
higher among patients with atrial fibrillation (3.1 per
100 patient-years) compared with other indications,
although the difference was not statistically significant.
The mean TTR of patients who died was significantly
lower (63.3%, SD 12.0) than who did not so (70.4%, SD
12.5, P < 0.03). The risk of mortality was significantly dif-
ferent depending on the following factors: follow-up
period (≤ 2 years versus > 2 years; OR 17.1, 95% CI 7.1–
40.8; P = 0.001), and TTR (≤ 65% versus > 65%; OR 2.3,
95% CI 1.5–4.0; P = 0.049;). Cox regression models (for
survival) were significantly different depending on: age
(≤ 60 years vs > 60 years, HR 0.4, 95% CI 0.6–0.9; P =
0.024), and TTR (≤ 65% versus > 65%; HR 3.0, 95% CI
1.5–6.3; P < 0.001 (Fig. 3). Of 59 patients who died, 34
(57.6%) did during first 2 years of follow-up. A total of
24 venous and arterial thromboembolic complications
(especially stroke, n = 20) were reported during the fol-
low-up period. Its incidence rate was 0.9 per 100 pa-
tient-years. The mean TTE was 20.6 months (SD 16.4).
Three of the complications were fatal: a pulmonary
thromboembolism and two cerebrovascular accidents.
The mean age of patients who suffered a thrombo-
embolic complication was significantly higher (68.8
years, SD 11.4) than those who did not so (61.1 years,
SD 13.8, P < 0.006). Cox regression models (for
thromboembolic complication) were significantly differ-
ent depending on age (≤ 60 years versus > 60, HR 0.4
95%CI 0.15–0.92; P = 0.030). No significant differences
in the incidence of thromboembolic complications were
found regarding TTR or target INR. A total of 117
hemorrhagic complications (11 of them major) were re-
ported during the study period. The incidence rate of
major hemorrhages was 0.5 per 100 patient-years. The
TTE (severe) was 18.9 months (SD 17.3). The mean TTE
was significantly lower for women than men (6.6 versus
Table 1 Demographic and clinical characteristics of patients
and treatments
Patients (N = 808)
Gender, n (%)
Male 499 (61.8)
Female 309 (38.2)
Age groups, n (%)
< 50 168 (20.8)
50–60 197 (24.4)
60–75 311 (38.5)
> 75 132 (16.3)
Origin of the patient, n (%)
Primary healthcare 340 (42.1)
Specialized healthcare 468 (57.9)
Anticoagulant agent, n (%)
Acenocoumarol 791 (97.9)
Warfarin 17 (2.1)
Target INR, n (%)
2.0–3.0 610 (75.5)
2.5–3.5 182 (22.5)
Other 16 (2.0)
Indication for anticoagulation, n (%)
Mechanical heart valve 204 (25.2)
Atrial fibrillation/ Atrial flutter 344 (42.6)
Venous and arterial thrombosis 111 (13.7)
Others 148 (18.3)
Unknown 1 (0.1)
Time of follow-up, median years (IQR) 3.3 (0.0–5.0)
Required a responsible caregiver to PSM a 107 (14.0)
Study withdrawal, n (%) 177 (21.9)
Death 59 (7.3)
End of treatment 42 (5.2)
Never performed PSM 36 (4.5)
Voluntary withdrawal 28 (3.5)
Loss to follow-up 8 (1.0)
Others 4 (0.5)
INR international normalized ratio, IQR interquartile range, PSM
patient self-management
a Data were not available in 42 patients
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22.3 months, P < 0.001). Gastrointestinal (n = 5) was the
most frequent major hemorrhagic complication. None of
hemorrhagic complications resulted in death. During the
first 2 years of follow-up occurred significantly more
cases of death (34 cases, 57.6%), and thromboembolic
(16 cases, 66.7%) and major hemorrhagic complications
(7 cases, 63.6%) than after 2 years (P < 0.001 in all cases).
The mean age of patients who experienced any event
(death or any complication; analyzed together, n = 82)
was significantly higher (70.2, SD 11.3) than those who
did not so (60.8, SD 13.7). The risk of experiencing an
event was significantly higher in patients who did not
required a responsible caregiver than who did so (OR
0.19, 95% CI 0.1–0.3; P < 0.001). The remaining demo-
graphic and clinical characteristics of patients showed
no significant correlations with experiencing an event.
Patients who performed the conventional management,
i.e. received training for PSM but never performed it
Table 2 Time in therapeutic range regarding demographic and clinical characteristics of patients
Median time in therapeutic range (%) P
Overall (n = 476) a 71.5
Gender < 0.026
Male 70.6
Female 72.6
Target INR < 0.001
2.0–3.0 73.9
2.5–3.5 65.6
Other 67.6
Indication for anticoagulation < 0.001
Mechanical heart valve (n = 125) 67.2
Atrial fibrillation/ Atrial flutter (n = 178) 73.5
Venous and arterial thrombosis (n = 57) 73.1
Others (n = 93) 71.7
a Patients included in the effectiveness analysis
Fig. 2 Evolution of the time in therapeutic range regarding target international normalized ratio. Different letters (a, b) indicate significant
differences (P < 0.01) between time points, whereas asterisks do between groups (2.0–3.0 versus 2.5–3.5)
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(n = 36), or who stopped PSM (n = 16) or continued with
routine monitoring (n = 68), had greater incidence rates
of complications: 2.4, 1.8, and 3.4 per 100 patient-years
for thromboembolic complications, major hemorrhagic
events, and mortality, respectively. The mean TTE was
29.4 months, 15.5 months and 20.8 months.
Discussion
During more than six decades, OACs with vitamin K
antagonists have been the standard treatment for pre-
venting thromboembolic events [17]. Nevertheless,
periodic visits to the healthcare center for monitoring
became a real problem for patients, especially those
with advanced age. The PSM has emerged, in part, with
the aim of solving such a limitation [5–7]. Results from
our study demonstrate the effectiveness and safety of
PSM for long-term periods of time in real-world set-
tings. To date, the evidence of PSM, demonstrating the
improvement in the quality of anticoagulation and the
reduction in complications, derives mainly from ran-
domized clinical studies (with strict inclusion and
exclusion criteria), and short-term periods of follow-up.
Henegan et al., [14] in a systematic review and meta-
analysis, involving 11 randomized trials and 6417
patients using PSM (self-testing and self-dosage),
demonstrated a significant reduction in thrombo-
embolic complications (Odd ratio, OR 0.51) but not in
hemorrhagic ones or deaths. Bloomfield et al., [18] in a
meta-analysis of 22 studies with 8413 patients assigned
to self-testing or PSM, revealed significant reduction in
thromboembolic complications (OR 0.58) and deaths
(OR 0.74). The time in therapeutic range has also been
proven to be longer in PSM (ranging between 61.3 and
83.0% after 12 months of follow-up) than using the
conventional management (61.0–70.8%) [19–22].
Menéndez-Jándula et al., [23] in a randomized trial
compared the efficacy and safety of PSM of OACs and
the conventional management in 737 Spanish patients
for a median of 11.8 months. No differences were found
between TTR using PSM (64.3%) and the conventional
management (64.9%). The number of major complica-
tions was higher in patients from the conventional
Fig. 3 Survival curves depending on age and time within therapeutic range, and probability of thromboembolic complication depending on age
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management (27) than PSM (8). In our knowledge, limited
studies have been specifically designed to long-term evalu-
ate effectiveness and safety of PSM in real-world settings
[24–28]. The summary of main studies involving PSM in
real-world settings are shown in Table 3. Fritschi et al.,
[24] in a study with 330 patients performing PSM in
Switzerland, reported a TTR of 72.0% after 2.8 years of fol-
low-up. The incidence rate of thromboembolic and major
hemorrhagic events was the same, 0.6 per 100 patient-
years. Matchar et al., [25] with 1463 patients performing
PSM, showed a TTR of 66.2%. Incidence rates of mortality
and major hemorrhages were 3.4 and 4.0 per 100 patient-
years. Nagler et al., [26] involving 1221 patients trained for
PSM and followed-up for a median of 4.3 years, showed a
TTR of 80%. The incidence rate of mortality, and
thromboembolic events, and hemorrhagic were 1.4, 0.9,
and 1.2 per 100 patient-years, respectively. Grove et al.,
[28] in a recent study aimed at comparing PSM of OACs
with direct OACs in patients with atrial fibrillation re-
vealed an annual incidence rate of 1.1 for mortality, 0.5 for
thromboembolic events, and 2.3 for major hemorrhages.
Results from our present study are in concordance with
literature, regarding TTR and incidence rates of events.
Significant differences in TTR between males and females
have been previously reported by other authors [29]; how-
ever, differences in TTR after 90 days since study start
have not been so. In our knowledge, there is not an easy
explanation for such observation. The mean TTE for pa-
tients in PSM was around 20months, and the highest pro-
portion of events occurred in the first 2 years, in contrast
with those who stopped PSM for any reason. The inci-
dence of complications and mortality was much higher in
patients who stopped performing PSM. In the case of
thromboembolic and hemorrhagic complications, the inci-
dence rate was more than two-fold.
One of the limitations of the study was the absence of
a proper control group, for comparison purposes. Al-
though a control group would have improved the design
of the study, we aimed at carrying out a study in real-
world conditions, and a large number of patients. Beside
this, and cautiously, the study also provides information
about patients who did not perform the PSM and con-
tinued in the conventional management (in low number,
due to the same nature of real-world settings). Further-
more, comparisons were possible by using the published
national and international literature. Another limitation
was the lack of some effectiveness data (only 58.9% of
patients downloaded the INR measurements). However,
this limitation was intrinsically associated to observa-
tional, clinical practice studies.
Conclusions
The PSM of OACs is effective for maintaining patients
within the INR therapeutic range for a long period of
time in routine clinical practice. Results of the present
study suggest that its effectiveness is at least comparable
to the conventional management. Moreover, it seems
safe in real-world settings, by preventing all-cause mor-
tality, and thromboembolic and major hemorrhagic
complications. Additional studies in clinical practice, in-
volving control groups and a larger cohort of patients
are required to corroborate these results.
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